Post-treatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer.
Feltl, D
Post-treatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer. [electronic resource] - Neoplasma 2005 - 393-7 p. digital
Publication Type: Journal Article
0028-2685
Adult
Aged
Antineoplastic Agents--therapeutic use
Biomarkers, Tumor--blood
Combined Modality Therapy
Female
Head and Neck Neoplasms--blood
Humans
Male
Middle Aged
Neoplasms, Squamous Cell--blood
Predictive Value of Tests
Prognosis
Radiotherapy
Transforming Growth Factor beta--analysis
Transforming Growth Factor beta1
Tumor Burden--drug effects
Post-treatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer. [electronic resource] - Neoplasma 2005 - 393-7 p. digital
Publication Type: Journal Article
0028-2685
Adult
Aged
Antineoplastic Agents--therapeutic use
Biomarkers, Tumor--blood
Combined Modality Therapy
Female
Head and Neck Neoplasms--blood
Humans
Male
Middle Aged
Neoplasms, Squamous Cell--blood
Predictive Value of Tests
Prognosis
Radiotherapy
Transforming Growth Factor beta--analysis
Transforming Growth Factor beta1
Tumor Burden--drug effects